Group 1: Company Performance - Kenvue Inc. (NYSE:KVUE) is recognized as one of the top-performing consumer staples stocks in February [1] - Barclays has raised its price target for KVUE to $19 from $18 while maintaining an Equal Weight rating following updates to the company model after the Q4 report [1][8] Group 2: Legal Issues - A Texas judge rejected Kenvue's request to dismiss a lawsuit filed by the state's attorney general, which alleges that Kenvue misrepresented Tylenol by not disclosing potential hazards for children when pregnant women take the medication [2][3] - The ruling allows the case to proceed in Texas courts, highlighting ongoing scrutiny of drug labeling and public health protections for pregnant women and children [4] Group 3: Company Overview - Kenvue Inc. is a consumer health company that develops and markets personal care and wellness products, including leading brands in skin care, baby care, and over-the-counter health categories [5]